BU08073 a buprenorphine analogue with partial agonist activity at μ‐receptors in vitro but long‐lasting opioid antagonist activity in vivo in mice

No abstract is available for this paper.

• Publication year

  2015

• Venue

  British Journal of Pharmacology

• Publication date

  2015-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/bph.12796PMID 24903063PMCID PMC4292977
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Challenges for opioid receptor nomenclature: IUPHAR Review 9

  2015cited by this paper
• A Real-Time, Fluorescence-Based Assay for Measuring µ-Opioid Receptor Modulation of Adenylyl Cyclase Activity in Chinese Hamster Ovary Cells

  2014cited by this paper
• Physical Presence of Nor-Binaltorphimine in Mouse Brain over 21 Days after a Single Administration Corresponds to Its Long-Lasting Antagonistic Effect on κ-Opioid Receptors

  2013cited by this paper
• Buprenorphine and related orvinols

  2013cited by this paper
• Orvinols with Mixed Kappa/Mu Opioid Receptor Agonist Activity

  2013cited by this paper
• Opioid receptors: toward separation of analgesic from undesirable effects.

  2013cited by this paper
• The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands

  2013cited by this paper
• The Concise Guide to Pharmacology 2013/14: G Protein-Coupled Receptors

  2013cited by this paper
• Rodent motor and neuropsychological behaviour measured in home cages using the integrated modular platform SmartCage™

  2012cited by this paper
• Crystal structure of the μ-opioid receptor bound to a morphinan antagonist

  2012cited by this paper
• TH-030418: a potent long-acting opioid analgesic with low dependence liability

  2011cited by this paper
• Duration of Action of a Broad Range of Selective κ-Opioid Receptor Antagonists Is Positively Correlated with c-Jun N-Terminal Kinase-1 Activation

  2011cited by this paper
• Comparison of the elevated plus and elevated zero mazes in treated and untreated male Sprague-Dawley rats: effects of anxiolytic and anxiogenic agents.

  2011cited by this paper
• Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.

  2011influential reference
• The First Universal Opioid Ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): Characterization of the In Vitro Profile and In Vivo Behavioral Effects in Mouse Models of Acute Pain and Cocaine-Induced Reward

  2011cited by this paper
• Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines

  2011cited by this paper
• The First Universal Opioid Ligand , ( 2 S )-2-[ ( 5 R , 6 R , 7 R

  2011cited by this paper
• Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling

  2010cited by this paper
• Guidelines for reporting experiments involving animals: the ARRIVE guidelines

  2010cited by this paper
• Nociceptin/Orphanin FQ Receptor Activation Attenuates Antinociception Induced by Mixed Nociceptin/Orphanin FQ/μ-Opioid Receptor Agonists

  2009cited by this paper
• Activities of mixed NOP and μ‐opioid receptor ligands

  2008influential reference
• Withdrawal from acute morphine dependence is accompanied by increased anxiety-like behavior in the elevated plus maze.

  2008cited by this paper
• Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist.

  2008cited by this paper
• Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In Vitro Studies

  2007cited by this paper
• Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.

  2007cited by this paper
• Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In Vivo Studies

  2007cited by this paper
• Long-Acting κ Opioid Antagonists Disrupt Receptor Signaling And Produce Noncompetitive Effects By Activating C-Jun N-Terminal Kinase*

  2007cited by this paper
• Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.

  2007cited by this paper
• Delta opioid receptor ligands modulate anxiety‐like behaviors in the rat

  2006cited by this paper
• Interactions of buprenorphine and dipotassium clorazepate on anxiety and memory functions in the mouse.

  2006cited by this paper
• IN VITRO METABOLISM STUDY OF BUPRENORPHINE: EVIDENCE FOR NEW METABOLIC PATHWAYS

  2005cited by this paper
• Kappa opioid antagonists: Past successes and future prospects

  2005cited by this paper
• Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats.

  2005cited by this paper
• The effect of a systemically active ORL-1 agonist, Ro 64-6198, on the acquisition, expression, extinction, and reinstatement of morphine conditioned place preference.

  2005cited by this paper
• The orvinols and related opioids--high affinity ligands with diverse efficacy profiles.

  2004cited by this paper
• Buprenorphine: a unique drug with complex pharmacology.

  2004cited by this paper
• Randomized Trial of Buprenorphine for Treatment of Concurrent Opiate and Cocaine Dependence

  2004cited by this paper
• Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats

  2004cited by this paper
• Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents.

  2004cited by this paper
• Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

  2004cited by this paper
• Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice

  2004cited by this paper
• Pharmacological properties of JDTic: a novel κ-opioid receptor antagonist

  2004cited by this paper
• Buprenorphine-Induced Antinociception Is Mediated by μ-Opioid Receptors and Compromised by Concomitant Activation of Opioid Receptor-Like Receptors

  2003cited by this paper
• Nociceptin inhibits acquisition of amphetamine-induced place preference and sensitization to stereotypy in rats.

  2003cited by this paper
• Guidelines for the care and use of mammals in neuroscience and behavioral research

  2003cited by this paper
• Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.

  2001cited by this paper
• Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor.

  2000cited by this paper
• Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay.

  1999cited by this paper
• Comparison of the effects of [Phe1Ψ(CH2‐NH)Gly2]Nociceptin (1–13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors

  1999cited by this paper
• A comparative study of the effects of morphine in the dorsal periaqueductal gray and nucleus accumbens of rats submitted to the elevated plus-maze test

  1999cited by this paper
• A new selective antagonist of the nociceptin receptor

  1998cited by this paper
• Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay

  1998cited by this paper
• Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.

  1998cited by this paper
• Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.

  1997cited by this paper
• Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.

  1995cited by this paper
• Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety

  1994cited by this paper
• Buprenorphine Treatment of Opiate and Cocaine Abuse: Clinical and Preclinical Studies

  1993cited by this paper
• Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test.

  1992cited by this paper
• Comparison of the effects

  1992cited by this paper
• Long term κ-opioid receptor blockade following nor-binaltorphimine

  1992cited by this paper
• Long term kappa-opioid receptor blockade following nor-binaltorphimine.

  1992cited by this paper
• Effects of intracerebroventricular beta-funaltrexamine on mu and delta opioid receptors in the rat: dichotomy between binding and antinociception.

  1991cited by this paper
• Effects of intracerebroventricular β-funaltrexamine on μ and δ opioid receptors in the rat: dichotomy between binding and antinociception

  1991cited by this paper
• Buprenorphine suppresses cocaine self-administration in rhesus monkeys.

  1989cited by this paper
• Pharmacology of opioids.

  1983cited by this paper
• The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone.

  1981cited by this paper
• A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities.

  1980cited by this paper
• AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT

  1977cited by this paper
• The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

  1976cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper

• Spinal blockade with intrathecal spiradoline and buprenorphine in rats.

  2025cites this paper
• Searching for Synthetic Opioid Rescue Agents: Identification of a Potent Opioid Agonist with Reduced Respiratory Depression.

  2024cites this paper
• Opioid Kullanım Bozukluğu ve Farmakolojik Tedavisinde Kullanılan İlaçlar

  2024cites this paper
• Hyperactivity in Mice Induced by Opioid Agonists with Partial Intrinsic Efficacy and Biased Agonism Administered Alone and in Combination with Morphine

  2023cites this paper
• Impact of Opioids on Cellular Metabolism: Implications for Metabolic Pathways Involved in Cancer

  2023cites this paper
• Molecular mechanisms of morphine tolerance and dependence; novel insights and future perspectives

  2023cites this paper
• Buprenorphine for Chronic Pain Management: a Narrative Review

  2023cites this paper
• An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Modulator Buprenorphine

  2023cites this paper
• Neurobiological mechanisms and related clinical treatment of addiction: a review

  2022cites this paper
• SLL-627 Is a Highly Selective and Potent κ Opioid Receptor (KOR) Agonist with an Unexpected Nonreduction in Locomotor Activity.

  2022cites this paper
• Buprenorphine: Far Beyond the “Ceiling”

  2021cites this paper
• Pharmacological Diversity in Opioid Analgesics: Lessons From Clinically Useful Drugs

  2021cites this paper
• The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies

  2021cites this paper
• A Critical Examination of the Mechanism of Action of Buprenorphine: Not Just a Mu Partial Agonist?

  2020cites this paper
• A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain

  2020cites this paper
• Opioid Overdose Deaths with Buprenorphine Detected in Postmortem Toxicology: a Retrospective Analysis

  2020cites this paper
• Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block

  2020cites this paper
• Buprenorphine exposures in adolescents and adults: a 10‐year experience of a French Poison Control Center

  2020cites this paper
• An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Receptor Modulator Buprenorphine

  2020cites this paper
• Molecular Biology of Opioid Analgesia and Its Clinical Considerations.

  2019cites this paper
• Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids

  2019cites this paper
• A Surface-Enhanced Raman Spectral Library of Important Drugs Associated With Point-of-Care and Field Applications

  2019cites this paper
• Prevention and Treatment of Opioid Misuse and Addiction: A Review

  2019cites this paper
• DARK Classics in Chemical Neuroscience: Opium, a Friend or Foe.

  2018cites this paper
• Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option

  2018cites this paper
• Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder

  2018cites this paper
• Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder

  2018cites this paper
• Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile

  2018cites this paper
• The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review

  2018cites this paper
• In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder

  2018cites this paper
• Endogenous Opiates and Behavior: 2015.

  2017cites this paper
• Buprenorphine differentially affects M1- and M2-polarized macrophages from human umbilical cord blood

  2017cites this paper
• Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians.

  2017cites this paper
• Random Forest Segregation of Drug Responses May Define Regions of Biological Significance

  2016cites this paper
• Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants

  2016cites this paper
• Kappa‐Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials

  2016cites this paper
• Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain

  2015cites this paper